tiprankstipranks
Telesis Bio (TBIO)
OTHER OTC:TBIO
US Market
Want to see TBIO full AI Analyst Report?

Telesis Bio (TBIO) Price & Analysis

140 Followers

TBIO Stock Chart & Stats

$0.05
-$0.01(-4.70%)
At close: 4:00 PM EST
$0.05
-$0.01(-4.70%)

Bulls Say, Bears Say

Bulls Say
Innovative Product OfferingThe company's focus on cutting-edge DNA synthesis technologies positions it well in the growing synthetic biology market, providing a durable competitive advantage.
Strategic PartnershipsPartnerships with biotech firms and research institutions enhance revenue potential and foster innovation, contributing to long-term growth.
Revenue DiversificationDiversified revenue sources reduce dependency on a single income stream, enhancing financial stability and resilience against market fluctuations.
Bears Say
High LeverageHeavy reliance on debt financing increases financial risk and limits flexibility, potentially impacting long-term sustainability if not managed properly.
Negative Cash FlowPersistent negative cash flow highlights challenges in operational efficiency, which may hinder the company's ability to invest in growth and innovation.
Declining RevenueA significant decline in revenue suggests potential market share loss or reduced demand, posing a threat to long-term growth prospects.

Telesis Bio News

TBIO FAQ

What was Telesis Bio’s price range in the past 12 months?
Telesis Bio lowest stock price was $0.01 and its highest was $0.15 in the past 12 months.
    What is Telesis Bio’s market cap?
    Telesis Bio’s market cap is $86.23K.
      When is Telesis Bio’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Telesis Bio’s earnings last quarter?
      Currently, no data Available
      Is Telesis Bio overvalued?
      According to Wall Street analysts Telesis Bio’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Telesis Bio pay dividends?
        Telesis Bio does not currently pay dividends.
        What is Telesis Bio’s EPS estimate?
        Telesis Bio’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Telesis Bio have?
        Telesis Bio has 78,393,530 shares outstanding.
          What happened to Telesis Bio’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Telesis Bio?
          Currently, no hedge funds are holding shares in TBIO
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Telesis Bio

            Telesis Bio, Inc., formerly known as Codex DNA, Inc. (and SGI-DNA, Inc. prior to that), is a San Diego, California-based synthetic biology company established in 2011. The company provides a comprehensive suite of instruments, reagents, and services for synthetic biology applications, catering primarily to pharmaceutical and academic laboratories worldwide. Its clientele also extends to government institutions, contract research organizations (CROs), and other synthetic biology enterprises. Among its core offerings is the BioXp system, a groundbreaking platform that empowers researchers to generate endpoint-ready synthetic DNA directly from digital sequences. Complementing this, the BioXp portal offers an intuitive online environment with guided workflows and design tools for constructing new DNA sequences and assembling them into desired vectors. For specific synthetic biology tasks, Telesis Bio supplies BioXp kits, which include essential building blocks and proprietary reagents like its well-known Gibson Assembly products. Additional solutions encompass cloud-based scripts and specialized benchtop reagents designed for post-BioXp system workflows. Through its Biofoundry Services, customers can commission and receive BioXp system-generated products, such as custom genes, clones, cell-free amplified DNA, and diverse variant libraries. The company also performs enzymatic DNA synthesis using short oligo ligation assembly techniques.

            Telesis Bio (TBIO) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Cytosorbents
            Xtant Medical Holdings
            TELA Bio
            Rapid Micro Biosystems
            Icecure Medical

            Ownership Overview

            0.06%99.94%
            Insiders
            Mutual Funds
            0.06% Other Institutional Investors
            99.94% Public Companies and
            Individual Investors
            Popular Stocks